News from twi pharmaceuticals, inc A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Jun 26, 2014, 11:26 ET

TWi Biotechnology Receives Notice of Patent Allowance for Its Lead Drug Candidate AC-201 in United States

TWi Biotechnology, Inc., today announced that it has received Notice of Allowance for AC-201, TWi Biotechnology's lead drug candidate, from United...

Apr 23, 2014, 05:50 ET

TWi Announces Settlement of Lidoderm(R) Patent Litigation

TWi Pharmaceuticals, Inc. today announced that it has entered into a settlement agreement with Endo Pharmaceuticals Inc., Teikoku Seiyaku Co., Ltd....

Apr 07, 2014, 05:45 ET

TWi Announces ANDA Approval of Generic Procardia XL(R) Tablets 30 mg, 60 mg and 90 mg in the United States

TWi Pharmaceuticals, Inc., today announces the ANDA approval of the generic equivalent to Procardia XL® (Nifedipine) Extended Release Tablets,...

Sep 10, 2013, 08:51 ET

TWi Biotechnology Receives Patent Allowance for Its Lead Drug Candidate AC-201 in the United States

TWi Biotechnology, Inc., today announced that it has received an official notification of patent allowance for AC-201, TWi Biotechnology's lead...

Jul 16, 2013, 10:47 ET

TWi Pharmaceuticals Receives Patent Allowance for Its Reduced Food Effect Metformin Controlled Release Formulation in United States

 TWi Pharmaceuticals, Inc., today announced that it has received an official notification of patent allowance for its metformin controlled...

Jun 17, 2013, 22:17 ET

TWi Biotechnology Announces Completion of Patient Enrollment in Gout Flare Prophylaxis Phase II Trial for AC-201

TWi Biotechnology, Inc. today announced that it has completed the patient enrollment in a phase II trial of AC-201 for Gout Flare Prophylaxis...

May 30, 2013, 08:29 ET

TWi Biotechnology Receives Patent Allowance for Its Lead Drug Candidate AC-201 in China

 TWi Biotechnology, Inc. today announced that it has received an official notification of patent allowance for AC-201, TWi Biotechnology's lead...

May 29, 2013, 05:07 ET

TWi Pharmaceuticals' Manufacturing Site for the Generic Version of Lidoderm(R) (Lidocane 5% patch) Passes US FDA cGMP Audit and Pre-Approval Inspection

TWi Pharmaceuticals, Inc., today announced that Teh Seng Pharmaceutical Mfg. Co. (Teh Seng), the manufacturing partner for its generic version of...

May 14, 2013, 07:54 ET

TWi Pharmaceuticals Announces Tentative ANDA Approval for Guanfacine Hydrochloride Extended-Release Tablets

TWi Pharmaceuticals, Inc. (Taiwan OTC: 4180) today announced that it has received tentative approval for its Abbreviated New Drug Application...

Aug 06, 2012, 06:00 ET

TWi Pharmaceuticals Announces Positive Phase IIb Clinical Trial Results of AC-201 in Patients with Type 2 Diabetes.

TWi Pharmaceuticals, Inc., a specialty pharmaceutical company based in Taiwan, today announced its fully owned subsidiary, TWi...